TELA Bio (TELA) Cash & Equivalents Growth (3y) (2021 - 2026)

TELA Bio (TELA) Cash & Equivalents Growth (3y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn -9.44%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 19.87%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 8.10%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 36.60%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn 40.99%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 21.52%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -0.70%
8 Smith & Nephew 26.99 Bn 26.41 Bn - 16.75%
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 34.11%
10 TELA Bio 38.36 Mn -1.18 Mn 12.52 Mn 9.49%

Historic Data

Download Data
DateValue
Mar 31, 2026 9.49%
Dec 31, 2025 6.56%
Sep 30, 2025 -18.17%
Jun 30, 2025 8.05%
Mar 31, 2025 9.06%
Dec 31, 2024 6.23%
Sep 30, 2024 -31.42%
Jun 30, 2024 -23.97%
Mar 31, 2024 -17.37%
Dec 31, 2023 -14.36%
Sep 30, 2023 -10.60%
Jun 30, 2023 -8.60%
Mar 31, 2023 -10.06%
Dec 31, 2022 -2.48%
Sep 30, 2022 71.76%
Dec 31, 2021 36.49%